Abstract 1055P
Background
Efficient infiltration of activated T cells into tumors plays an important role in the therapeutic effect of adoptive cell immunotherapy. We previously modified T cells with a tumor-penetrating peptide iRGD (SmarT cells), and demonstrated that SmarT cells promote tumor-specific lymphocyte infiltration and enhanced the antitumor efficacy of PD-1 blocking strategy.
Methods
Here we report the interim analysis results of an ongoing phase 1/2 dose-escalation clinical trial of SmarT plus PD-1 mAb in patients with previously treated solid cancers (ChiCTR2200061306). The primary objective was safety for the combination of SmarT cells, low dose radiation and PD-1 mAb; secondary objectives included efficacy and dose-finding of SmarT cells. We treated 10 patients with three SmarT doses: 1.0 × 109, 5.0 × 109 or 1.0 × 109 cells. The low dose radiation (1Gy) was carried out 24 hours before SmarT injection.
Results
Three patients experienced a grade 2 fever. Two patients experienced a grade anemia. No cytokine release syndrome (CRS) occurred. No grade 3 or higher treatment-related adverse events or deaths were reported. A total of three patients had stable disease (SD) and seven patients had a progressive disease (PD). The disease control rate (DCR) reached 30.0%. The median progressive free survival time (mPFS) was 71 days and the median overall survival time (mOS) was 201 days.
Conclusions
These initial results suggest that SmarT cells has promising efficacy with an acceptable safety profile in patients with heavily pretreated, solid cancers.
Clinical trial identification
The trial protocol number is ChiCTR2200061306 and the release date 20 June 2022.
Editorial acknowledgement
Legal entity responsible for the study
The Ethics Committee of Nanjing Drum Tower Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1333P - A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations
Presenter: Min Hee Hong
Session: Poster session 19
1334P - Activity of first line immunotherapy or chemo-immunotherapy in advanced NSCLC with SMARCA4 deficiency
Presenter: Alina Grecea
Session: Poster session 19
1335P - Phase Ib study to evaluate the safety and tolerability of osimertinib with ipilimumab in EGFRm NSCLC
Presenter: Sonam Puri
Session: Poster session 19
1336P - Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy
Presenter: Felix Saalfeld
Session: Poster session 19
1337P - Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study
Presenter: Lin Wu
Session: Poster session 19
1338P - Cerebrospinal fluid pharmacokinetic study of lazertinib and pemetrexed in patients with EGFR-mutant non-small cell lung cancer with leptomeningeal metastases: KCSG21-01 LAZARUS trial
Presenter: Bhumsuk Keam
Session: Poster session 19
1339P - Real-world experience of dacomitinib in mEGFR Advanced NSCLC: A single centre experience
Presenter: Bivas Biswas
Session: Poster session 19
1340P - Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non–small cell lung cancer: A Chinese, multicenter, real-world cohort study
Presenter: Dongming Zhang
Session: Poster session 19
1341P - Real-world molecular testing, treatment patterns and clinical outcomes in Chinese advanced NSCLC patients, who have progressed on first-line EGFR-TKI therapy (PISCES)
Presenter: Panwen Tian
Session: Poster session 19
1342P - Effect of the timing of intervention in craniocerebral radiotherapy on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis
Presenter: Guangchuan Deng
Session: Poster session 19